Business Context and Reporting Period
This Form 8-K Current Report was filed by GoodRx Holdings, Inc. on May 30, 2023. The filing discloses a specific corporate governance event regarding executive compensation rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a specific executive compensation amount.
- Retention Bonus: $500,000 cash bonus approved for Chief Operating Officer Raj Beri.
Material Changes
The material change reported is the Board of Directors' approval of a Retention Bonus Agreement with Raj Beri, effective June 1, 2023. This agreement establishes a one-year retention period (May 24, 2023, through May 24, 2024) during which the bonus is subject to forfeiture if Mr. Beri resigns without "good reason" or is terminated for "cause."
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or general risk factors. The primary contingency noted is the forfeiture of the $500,000 bonus if the executive departs under specific conditions. If Mr. Beri is involuntarily terminated for reasons other than "cause," he is entitled to a pro-rata portion of the bonus based on time served.
Investor Verification Checklist
- Verify the full terms of the Retention Bonus Agreement (Exhibit 10.1) for definitions of "good reason" and "cause."
- Confirm the payment timeline, which is scheduled for the payroll following the end of the retention period or termination date.
- Review subsequent filings to determine if the bonus was ultimately paid or forfeited.